Genmab A/S

Healthcare · Biotechnology · Denmark

Last price 56.49 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 33.81B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell n...